Jahnen, Matthias;Amiel, Thomas;Wagner, Tobias;Kirchhoff, Florian;Büchler, Jakob W;Düwel, Charlotte;Koll, Florestan;Westenfelder, Kay;Horn, Thomas;Herkommer, Kathleen;Meissner, Valentin H;Gschwend, Jürgen E;Lunger, Lukas
Does experience change the role of systematic biopsy during MRI-fusion biopsy of the prostate?
World J Urol
2023
41
10
2699-2705

Schober, Sebastian Johannes;Schoening, Caroline;Eck, Jennifer;Middendorf, Charlotte;Lutsch, Julia;Knoch, Pia;von Ofen, Anna Josefine;Gassmann, Hendrik;Thiede, Melanie;Hauer, Julia;Kolk, Andreas;Mantwill, Klaus;Gschwend, Jürgen E;Burdach, Stefan E G;Nawroth, Roman;Thiel, Uwe;Holm, Per Sonne
The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma.
Clin Cancer Res
2023
29
10
1996-2011

Ehrenfeld, Maximilian;Segeth, Felicia;Mantwill, Klaus;Brockhaus, Corinna;Zhao, Yuling;Ploner, Christian;Kolk, Andreas;Gschwend, Jürgen E;Nawroth, Roman;Holm, Per Sonne
Targeting Cell Cycle Facilitates E1A-Independent Adenoviral Replication.
J Virol
2023
97
6

Meissner, Valentin H;Simson, Barbara W;Dinkel, Andreas;Schiele, Stefan;Ankerst, Donna P;Lunger, Lukas;Gschwend, Jürgen E;Herkommer, Kathleen
Treatment decision regret in long-term survivors after radical prostatectomy: a longitudinal study.
BJU Int
2023
131
5
623-630

Lunger, Lukas;Meissner, Valentin H;Kopp, Benedikt C G;Dinkel, Andreas;Schiele, Stefan;Ankerst, Donna P;Gschwend, Jürgen E;Herkommer, Kathleen
Prevalence and determinants of decision regret in long-term prostate cancer survivors following radical prostatectomy.
BMC Urol
2023
23
1

Ohlmann, Carsten-Henning;Jäschke, Michelle;Jaehnig, Peter;Krege, Susanne;Gschwend, Jürgen;Rexer, Heidrun;Junker, Kerstin;Zillmann, Roger;Rüssel, Christoph;Hellmis, Eva;Suttmann, Henrik;Janssen, Martin;Marin, Jan;Hübner, Andreas;Mathers, Michael;Gleißner, Jochen;Scheffler, Michael;Feyerabend, Susan;Telle, Jens;Klier, Jörg;Stöckle, Michael
Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial.
Prostate Cancer Prostatic Dis
2023
26
4

Hensley, Patrick J;Seiler, Roland;Herr, Harry;Mouw, Kent W;Iyer, Gopa;Dyrskjøt, Lars;Nawroth, Roman;Goebell, Peter;Schmitz-Drager, Bernd;Todenhofer, Tilman;Black, Peter C;Kamat, Ashish M;Williams, Stephen B
Bladder preservation after neoadjuvant therapy - 2021 IBCN updates part 1.
Urol Oncol
2023
41
7
307-312

Ecke, Thorsten H;Wirtz, Ralph M;Friedersdorff, Frank;Füssel, Susanne;Hoffmann, Michèle J;Gaisa, Nadine T;Nawroth, Roman
[Research in bladder cancer: translation into the clinic-report of 13th annual meeting of the German Research Group on Bladder Cancer (DFBK) in Berlin].
Urologie
2023
62
6
636-639

Klümper, Niklas;Ralser, Damian J;Ellinger, Joerg;Roghmann, Florian;Albrecht, Julia;Below, Eduard;Alajati, Abdullah;Sikic, Danijel;Breyer, Johannes;Bolenz, Christian;Zengerling, Friedemann;Erben, Philipp;Schwamborn, Kristina;Wirtz, Ralph M;Horn, Thomas;Nagy, Dora;Toma, Marieta;Kristiansen, Glen;Büttner, Thomas;Hahn, Oliver;Grünwald, Viktor;Darr, Christopher;Erne, Eva;Rausch, Steffen;Bedke, Jens;Schlack, Katrin;Abbas, Mahmoud;Zschäbitz, Stefanie;Schwab, Constantin;Mustea, Alexander;Adam, Patrick;Manseck, Andreas;Wullich, Bernd;Ritter, Manuel;Hartmann, Arndt;Gschwend, Juergen;Weichert, Wilko;Erlmeier, Franziska;Hölzel, Michael;Eckstein, Markus
Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.
Clin Cancer Res
2023
29
8
1496-1505

Heinzelbecker, Julia;Spieler, Natalie;Kuehn, Michael;Fischer, Claus;Volkmer, Björn;von Rundstedt, Friedrich;Albers, Peter;Becht, Eduard;Bannowsky, Andreas;Weber, H Matthias;Hofmann, Rainer;Müller, Markus;Langbein, Sigrun;Steiner, Gabriel;Retz, Margitta;Kamradt, Jörn;Wagenpfeil, Gudrun;Wellek, Stefan;Lehmann, Jan;Stoeckle, Michael
Adjuvant vs. progression-triggered treatment with gemcitabine in platinum-ineligible high-risk bladder cancer patients: Long-term follow-up of a randomized phase 3 trial.
Urol Oncol
2023
41
8
356.e19-356.e30